Hydreight Announces Normal Course Issuer Bid

Executive Summary

• Hydreight Technologies Inc. announces a normal course issuer bid to repurchase up to 4,951,189 common shares (≈9.27% of outstanding shares, ≈10% of public float).
• The bid will run from March 12, 2026 until March 11, 2027 (or earlier at the Company’s option) and will be funded from existing working capital.
• Purchases will be made on the open market at prevailing market prices; the bid is intended to support an orderly market and enhance shareholder value.

Key Details

• Maximum Shares Targeted: 4,951,189 common shares (≈9.27% of total outstanding shares).
• Public Float Impact: Approximately 10.0% of the Company’s public float of 49,511,894 shares.
• Bid Period: Commences March 12 2026 and terminates March 11 2027, unless completed earlier or terminated at the Company’s discretion.
• Execution Agent: Research Capital Corporation (Vancouver, BC) will conduct the bid on behalf of Hydreight.
• Purchase Method: Open‑market purchases through TSX Venture Exchange facilities; price paid equals the prevailing market price at time of each purchase.
• Funding Source: Existing working capital – no external financing required.
• Regulatory Disclosure: A summary of the bid will be included in the management information circular for the next shareholders’ meeting, per exchange policies.
• Management Commentary: CEO Shane Madden stated that the bid provides flexibility to allocate capital disciplinedly and aims to create additional value for shareholders given perceived undervaluation of the stock.

Notable Quotes

“Hydreight has continued to demonstrate strong operational momentum as we scale our digital health infrastructure platform across the United States… The normal course issuer bid provides us with the flexibility to allocate capital in a disciplined manner while creating additional value for our shareholders.” – Shane Madden, Director and Chief Executive Officer